Study Summary
This trial is testing if a patient's DNA can predict if they will have a successful kidney transplant with just one immunosuppressive drug, instead of the multiple drugs typically required.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 7 Secondary · Reporting Duration: 12 months after the start of immunosuppression wean
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
Immunosuppression Taper
1 of 1
Experimental Treatment
25 Total Participants · 1 Treatment Group
Primary Treatment: Belatacept · No Placebo Group · Phase 4
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any vacancies for prospective participants in this experiment?
"Yes, according to clinicaltrials.gov records this medical trial is currently enrolling candidates with the original posting taking place on July 28th 2021 and edits being made as recently as December 30th 2021." - Anonymous Online Contributor
Are there any prior studies that have incorporated Belatacept in their research?
"Currently, 12 studies for Belatacept are active with 1 trial in the third stage. San Francisco is a major centre for this medication's clinical trials; however, there are 48 total locations across America running these experiments." - Anonymous Online Contributor
What risks are associated with the usage of Belatacept?
"The safety of Belatacept was assessed at 3, denoting its Phase 4 classification and consequently approved status." - Anonymous Online Contributor
How many participants are taking part in this clinical trial?
"Affirmative. According to the data posted on clinicaltrials.gov, this study that was published on July 28th 2021 is still recruiting patients and has opened 1 site for enrollment of 25 participants." - Anonymous Online Contributor
Does this experiment herald a new era of research?
"Belatacept has undergone a series of trials since its initial study in 2018, which was sponsored by Rho Federal Systems Division, Inc. Following the first Phase 1 trial involving 6 participants, Belatacept received approval for widespread use and currently there are 12 active investigations underway across 8 different nations." - Anonymous Online Contributor